The acquisition of iota Biosciences by Astellas Pharma is a massive "proof of concept" for the entire sector. While iota focuses on deep-tissue implants, the deal provides a significant boost to BioElectronics Corp (BIEL) by validating the science of using electrical pulses to treat chronic conditions.
Here is a breakdown of the key differences between the two technologies and how they position BIEL in the market:
Comparison of Technologies
Form Factor and Delivery:
iota Biosciences: Focuses on implantable "neural dust"—tiny sensors that must be surgically placed inside the body.
BioElectronics Corp: Focuses on wearable devices (like ActiPatch and RecoveryRx) that are applied externally to the skin.
Power and Mechanism:
iota Biosciences: Uses ultrasound to power and communicate with deep-tissue implants without batteries.
BioElectronics Corp: Uses battery-powered Pulsed Shortwave Therapy (PSWT) to modulate nerve activity and reduce inflammation from outside the body.
Market Access and Regulation:
iota Biosciences: Operates primarily in the surgical and prescription space, requiring intensive clinical trials and invasive procedures.
BioElectronics Corp: Operates in the Over-the-Counter (OTC) and prescription markets, offering a lower barrier to entry for patients.
Commercial Maturity:
iota Biosciences: Currently in the pre-clinical and early feasibility stages, focused on future breakthroughs.
BioElectronics Corp: Is already commercialized, with multiple FDA clearances and products currently available for sale.
Why this benefits BIEL:
The $429 million price tag on iota shows that Big Pharma is willing to pay a premium for bioelectronic intellectual property. For BIEL, this is a major win because it proves that non-drug therapies are no longer "alternative medicine"—they are a core part of the future of healthcare. As Astellas and Google (Verily) spend millions to educate doctors on bioelectronics, BIEL stands to gain as the more affordable, non-invasive, and "ready-to-buy" option in the marketplace.
Here is a breakdown of the key differences between the two technologies and how they position BIEL in the market:
Comparison of Technologies
Form Factor and Delivery:
iota Biosciences: Focuses on implantable "neural dust"—tiny sensors that must be surgically placed inside the body.
BioElectronics Corp: Focuses on wearable devices (like ActiPatch and RecoveryRx) that are applied externally to the skin.
Power and Mechanism:
iota Biosciences: Uses ultrasound to power and communicate with deep-tissue implants without batteries.
BioElectronics Corp: Uses battery-powered Pulsed Shortwave Therapy (PSWT) to modulate nerve activity and reduce inflammation from outside the body.
Market Access and Regulation:
iota Biosciences: Operates primarily in the surgical and prescription space, requiring intensive clinical trials and invasive procedures.
BioElectronics Corp: Operates in the Over-the-Counter (OTC) and prescription markets, offering a lower barrier to entry for patients.
Commercial Maturity:
iota Biosciences: Currently in the pre-clinical and early feasibility stages, focused on future breakthroughs.
BioElectronics Corp: Is already commercialized, with multiple FDA clearances and products currently available for sale.
Why this benefits BIEL:
The $429 million price tag on iota shows that Big Pharma is willing to pay a premium for bioelectronic intellectual property. For BIEL, this is a major win because it proves that non-drug therapies are no longer "alternative medicine"—they are a core part of the future of healthcare. As Astellas and Google (Verily) spend millions to educate doctors on bioelectronics, BIEL stands to gain as the more affordable, non-invasive, and "ready-to-buy" option in the marketplace.
2
